Abstract
The first step in evaluating a patient with rapidly progressive weakness is to ensure respiratory stability, intubating the patient if necessary. Measurements of negative inspiratory force and forced vital capacity help to determine which patients are in urgent need of intubation or closer respiratory monitoring. Once respiratory stability is ensured, identifying the initial pattern of weakness is the next step in establishing the diagnosis. Nerve conduction studies, electromyography, and other laboratory tests can then be used to differentiate among the various causes of weakness. The most important causes of rapidly progressive weakness are Guillain-Barre syndrome (GBS) and myasthenic crisis. Less common causes of rapidly progressive weakness include botulism, poliomyelitis, and spinal cord infarction. Critical illness neuromyopathy is a common source of failure to wean from the ventilator seen in patients who have undergone prolonged treatment in the ICU.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Hughes JM, Blumenthal JR, Merson MH, et al. Botulinum stool and serum testing - clinical features of types A and B food-borne botulism. Ann Intern Med. 1981;95:442–5.
Gordon PH, Wilbourn AJ. Early electrodiagnostic findings in Guillain-Barre syndrome. Arch Neurol. 2001;58:913–7.
Cornblath DR, McArthur JC, Kennedy PG, Witte AS, Griffin JW. Inflammatory demyelinating peripheral neuropathies associated with human T-cell lymphotropic virus type III infection. Ann Neurol. 1987;21:32–40.
Hughes RAC, Raphael JC, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2006;(1):CD002063.
Raphael JC, Chevret S, Hughes RAC, Annane D. Plasma exchange for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2002;(2):CD001798.
van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med. 1992;326:1123–9.
Gajdos P, Chevret S, Clair B, Tranchant C, Chastang C. Clinical trial of plasma exchange and high dose immunoglobulin in myasthenia gravis. Ann Neurol. 1997;41:789–96.
Guptill JT, Sanders DB, Evoli A. Anti-MuSK antibody myasthenia gravis: clinical findings and response to treatment in two large cohorts. Muscle Nerve. 2011;44:36–40.
Werner SB, Passaro D, McGee J, Schechter R, Vugia DJ. Wound botulism in California, 1951-1998: recent epidemic in heroin injectors. Clin Infect Dis. 2000;31:1018–24.
McCroskey LM, Hatheway CL. Laboratory findings in four cases of adult botulism suggest colonization of the intestinal tract. J Clin Microbiol. 1988;26:1052–4.
Petersen LR, Marfin AA. West Nile virus: a primer for the clinician. Ann Intern Med. 2002;137:173–9.
De Jonghe B, Sharshar T, Lefaucheur JP, et al. Paresis acquired in the intensive care unit. A prospective multicenter study. JAMA. 2002;288:2859–67.
Bolton CF, Gilbert JJ, Hahn AF, Sibbald WJ. Polyneuropathy in critically ill patients. J Neurol Neurosurg Psychiatry. 1984;47:1223–31.
Lacomis D, Giuliani MJ, Van Cott A, Kramer DJ. Acute myopathy of intensive care: clinical, electromyographic, and pathological aspects. Ann Neurol. 1996;40:645–54.
Rich MM, Bird SJ, Raps EC, McCluskey LF, Teener JW. Direct muscle stimulation in acute quadriplegic myopathy. Muscle Nerve. 1997;20:665–73.
Gooch JL. AAEM Case Report #29: prolonged paralysis after neuromuscular blockade. Muscle Nerve. 1995;18:937–42.
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Tarulli, A. (2021). Rapidly Progressive Weakness. In: Neurology. Springer, Cham. https://doi.org/10.1007/978-3-030-55598-6_12
Download citation
DOI: https://doi.org/10.1007/978-3-030-55598-6_12
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-55597-9
Online ISBN: 978-3-030-55598-6
eBook Packages: MedicineMedicine (R0)